About Us

Welcome to Tokai Pharmaceuticals

Tokai Pharmaceuticals is developing and commercializing novel therapies for prostate cancer and other hormonally-driven diseases. The companys lead drug candidate, galeterone, is a highly selective, multi-targeted, oral small molecule drug candidate for the treatment of prostate cancer that disrupts androgen receptor (AR) signaling via three distinct mechanisms of action: